跳至主要内容
临床试验/NCT00322283
NCT00322283已完成2 期

Efficacy and Safety of Oglemilast in the Prevention of Exercise-Induced Bronchospasm

Forest Laboratories1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2006年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
24
试验地点
1
主要终点
To determine the efficacy of oglemilast as compared to placebo in preventing exercise-induced asthma following 15 days of treatment.

研究概览

简要总结

The purpose of this study is to determine whether it is effective in the treatment of exercise-induced asthma and investigate the safety of oglemilast.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Prevention
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • stable mild asthma patients who exhibit at least a 20% decrease in FEV1 following exercise.

排除标准

  • pulmonary disease other than asthma, psychiatric illness, active cardiac disease, high blood pressure, history of substance abuse, current smokers.

研究组 & 干预措施

Oglemilast

Experimental

干预措施: Oglemilast (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

To determine the efficacy of oglemilast as compared to placebo in preventing exercise-induced asthma following 15 days of treatment.

次要结局

  • To evaluate the safety of oglemilast over 2 weeks as determined by adverse events, physical examinations, vital signs, electrocardiograms, and laboratory examinations.

研究者

发起方
Forest Laboratories
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验